{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:06:17Z","timestamp":1790809577530,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic acidosis is common in chronic kidney disease (CKD). However, when the severity of acidosis is disproportionate to renal dysfunction, exogenous causes must be excluded. Topical carbonic anhydrase inhibitors (CAIs) used for glaucoma are commonly perceived as locally acting; in patients with normal renal function their plasma free-drug concentrations are far below those required for systemic effects. In CKD, however, reduced clearance and reduced renal acid-excretory reserve can unmask systemic toxicity. Individual recognition of the syndrome remains uncommon at the bedside, particularly when it presents in the context of acute-on-chronic kidney injury, where its laboratory features can be obscured by acute kidney injury(AKI)-related acidosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 73-year-old Asian male with stage 3 CKD and glaucoma presented with progressive dyspnea, anorexia, and a 3-kg weight loss one month after starting fixed-combination brinzolamide 1% \/ timolol 0.5% eye drops. Laboratory evaluation revealed severe metabolic acidosis (pH 7.29; serum bicarbonate 8.9 mmol\/L, from a pre-exposure baseline of 20.3 mmol\/L) and acute-on-chronic kidney injury (creatinine 3.9\u00a0mg\/dL versus baseline\u2009~\u20092.0\u00a0mg\/dL). The disturbance was mixed: a delta-delta ratio of 0.42 (calculated using a reference normal serum bicarbonate of 24 mmol\/L) indicated a substantial non-anion-gap (hyperchloremic) component superimposed on a smaller high-anion-gap component, with hypokalemia (K\n                      <jats:sup>+<\/jats:sup>\n                      3.3 mmol\/L), hyperchloremia (Cl\n                      <jats:sup>-<\/jats:sup>\n                      107 mmol\/L), positive urine anion gap (+\u200933.4 mmol\/L), and a fractional excretion of bicarbonate of 4.3% measured during established acidosis (without bicarbonate loading). Other causes of metabolic acidosis were systematically excluded. Causality assessment by the Naranjo Adverse Drug Reaction Probability Scale yielded a score of 7 (probable). Discontinuation of the ophthalmic solution and alkali therapy resulted in the resolution of acidosis and recovery of renal function to baseline within one week, sustained at one-year follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Topical CAIs can undergo significant systemic absorption, bypassing first-pass metabolism, and precipitate life-threatening acidosis in patients with reduced renal reserve. Clinicians must maintain a high index of suspicion for ophthalmic medications as hidden causes of mixed acid-base disorders in patients with CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-05167-7","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T02:13:36Z","timestamp":1783390416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Severe metabolic acidosis with renal tubular acidosis features attributed to topical brinzolamide in a patient with stage 3 chronic kidney disease: a case report"],"prefix":"10.1186","volume":"27","author":[{"given":"Ming-Yuan Victor","family":"Chao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"5167_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1053\/j.ajkd.2015.08.028","volume":"67","author":"JA Kraut","year":"2016","unstructured":"Kraut JA, Madias NE. Metabolic Acidosis of CKD: An Update. Am J Kidney Dis. 2016;67:307\u201317. https:\/\/doi.org\/10.1053\/j.ajkd.2015.08.028.","journal-title":"Am J Kidney Dis"},{"key":"5167_CR2","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2147\/OPTH.S118409","volume":"10","author":"A Farkouh","year":"2016","unstructured":"Farkouh A, Frigo P, Czejka M. Systemic side effects of eye drops: a pharmacokinetic perspective. Clin Ophthalmol Auckl N Z. 2016;10:2433\u201341. https:\/\/doi.org\/10.2147\/OPTH.S118409.","journal-title":"Clin Ophthalmol Auckl N Z"},{"key":"5167_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1089\/jop.1997.13.23","volume":"13","author":"TH Maren","year":"1997","unstructured":"Maren TH, Conroy CW, Wynns GC, Levy NS. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. J Ocul Pharmacol Ther. 1997;13:23\u201330. https:\/\/doi.org\/10.1089\/jop.1997.13.23.","journal-title":"J Ocul Pharmacol Ther"},{"key":"5167_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2174\/138161208783877866","volume":"14","author":"F Mincione","year":"2008","unstructured":"Mincione F, Scozzafava A, Supuran CT. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14:649\u201354. https:\/\/doi.org\/10.2174\/138161208783877866.","journal-title":"Curr Pharm Des"},{"key":"5167_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrd2467","volume":"7","author":"CT Supuran","year":"2008","unstructured":"Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7:168\u201381. https:\/\/doi.org\/10.1038\/nrd2467.","journal-title":"Nat Rev Drug Discov"},{"key":"5167_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/bjo.2005.075622","volume":"90","author":"GJ Menon","year":"2006","unstructured":"Menon GJ, Vernon SA. Topical brinzolamide and metabolic acidosis. Br J Ophthalmol. 2006;90:247\u20138. https:\/\/doi.org\/10.1136\/bjo.2005.075622.","journal-title":"Br J Ophthalmol"},{"key":"5167_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/bcp.13499","volume":"84","author":"I Hoffmanov\u00e1","year":"2018","unstructured":"Hoffmanov\u00e1 I, S\u00e1nchez D. Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function. Br J Clin Pharmacol. 2018;84:796\u20139. https:\/\/doi.org\/10.1111\/bcp.13499.","journal-title":"Br J Clin Pharmacol"},{"key":"5167_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ajo.2023.05.007","volume":"253","author":"Y-C Wang","year":"2023","unstructured":"Wang Y-C, Ling XC, Tsai W-H, Liu J-S, Kuo K-L. Risks of Topical Carbonic Anhydrase Inhibitors in Glaucoma Patients With Chronic Kidney Disease: A Nationwide Population-Based Study. Am J Ophthalmol. 2023;253:49\u201355. https:\/\/doi.org\/10.1016\/j.ajo.2023.05.007.","journal-title":"Am J Ophthalmol"},{"key":"5167_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"key":"5167_CR10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1159\/000500042","volume":"49","author":"N Goraya","year":"2019","unstructured":"Goraya N, Munoz-Maldonado Y, Simoni J, Wesson DE. Fruit and Vegetable Treatment of Chronic Kidney Disease-Related Metabolic Acidosis Reduces Cardiovascular Risk Better than Sodium Bicarbonate. Am J Nephrol. 2019;49:438\u201348. https:\/\/doi.org\/10.1159\/000500042.","journal-title":"Am J Nephrol"},{"key":"5167_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/sj.ki.5002020","volume":"71","author":"JM Purkerson","year":"2007","unstructured":"Purkerson JM, Schwartz GJ. The role of carbonic anhydrases in renal physiology. Kidney Int. 2007;71:103\u201315. https:\/\/doi.org\/10.1038\/sj.ki.5002020.","journal-title":"Kidney Int"},{"key":"5167_CR12","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.2215\/CJN.07400715","volume":"10","author":"LL Hamm","year":"2015","unstructured":"Hamm LL, Nakhoul N, Hering-Smith KS. Acid-Base Homeostasis. Clin J Am Soc Nephrol. 2015;10:2232\u201342. https:\/\/doi.org\/10.2215\/CJN.07400715.","journal-title":"Clin J Am Soc Nephrol"},{"key":"5167_CR13","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1097\/01.asn.0000023430.92674.e5","volume":"13","author":"J Rodr\u00edguez Soriano","year":"2002","unstructured":"Rodr\u00edguez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol. 2002;13:2160\u201370. https:\/\/doi.org\/10.1097\/01.asn.0000023430.92674.e5.","journal-title":"J Am Soc Nephrol"},{"key":"5167_CR14","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1093\/eurheartj\/ehad557","volume":"44","author":"E Meekers","year":"2023","unstructured":"Meekers E, Dauw J, Martens P, Dhont S, Verbrugge FH, Nijst P, et al. Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial. Eur Heart J. 2023;44:3672\u201382. https:\/\/doi.org\/10.1093\/eurheartj\/ehad557.","journal-title":"Eur Heart J"},{"key":"5167_CR15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1523-1755.2004.00801.x","volume":"66","author":"S Kim","year":"2004","unstructured":"Kim S, Lee JW, Park J, Na KY, Joo KW, Ahn C, et al. The urine-blood PCO gradient as a diagnostic index of H(+)-ATPase defect distal renal tubular acidosis. Kidney Int. 2004;66:761\u20137. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00801.x.","journal-title":"Kidney Int"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05167-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05167-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05167-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:40:39Z","timestamp":1790808039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05167-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5167"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05167-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8899942\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a single-patient case report and does not constitute research on a defined cohort. Under the institutional policy of Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, single-patient case reports for which written informed consent has been obtained from the patient are exempt from formal Research Ethics Committee approval; this exemption has been confirmed by the institutional Research Ethics Committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"577"}}